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Background: There is a dearth of literature on the impact of TB/HIV co-infection on quality of life (QoL). We
conducted a study to assess the change in QoL over a 6-months period and its predictors among HIV-infected
patients with and without TB in Ethiopia.
Methods: 465 HIV-infected patients without TB and 124 TB/HIV co-infected patients were enrolled in a prospective
study in February, 2009. 455 (98%) HIV-infected and 97 (78%) TB/HIV co-infected patients were followed for 6
months. Data on QoL at baseline and 6th month were collected by trained nurses through face to face interviews
using the short Amharic version of the World Health Organization Quality of Life Instrument for HIV clients
(WHOQOL HIV-Brief). Common Mental Disorder (CMD) was assessed using a validated version of the Kessler-10
scale. Multivariate analysis was conducted using generalized estimating equations (GEE) using STATA to assess
change in QoL and its predictors.
Results: There was a statistically significant improvement of the physical, psychological, social, environmental and
spiritual QoL at the 6th months follow up compared to the baseline for both groups of patients (P < 0.0001). The
change in QoL in all dimension were more marked for TB/HIV co-infected patients compared to HIV-infected
patients without TB.
A severe form of CMD was strongly associated with poorer physical QoL among TB/HIV co-infected individuals
(β = −2.84; P = 0.000) and HIV clients without TB (β = −2.34; P = 0.000).
Conclusion: This study reveals that ART and anti-TB treatment significantly improve the QoL particularly among
TB/HIV co-infected patients. We recommend that the ministry of health in collaboration with partners shall integrate
mental health services into the TB/HIV programs and train health care providers to timely identify and treat CMD to
improve QoL.
Keywords: TB/HIV co-infection, Quality of life, Antiretroviral treatment, Common mental disorders, EthiopiaBackground
The advent of anti-retroviral therapy (ART) and its
widespread availability in many settings has reduced the
mortality rate among people living with HIV/AIDS
(PLHA) [1]. As longevity of PLHA improves as a result
of ART, improvement of quality of life (QoL) of these
patients has become an important issue for researchers
and policy makers [2]. According to the World Health* Correspondence: amare_deribew@yahoo.com
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reproduction in any medium, provided the orOrganization (WHO), QoL is defined as an individuals’
perception of their position in life in the context of the
culture and value systems in which they live and in relation
to their goals, expectations, standards and concerns [2].
This definition considers individuals’ satisfaction on their
physical, psychological, social relationships, environment,
and spiritual aspects of their life [3].
In addition to its biological and physical burden, HIV/
AIDS is associated with many social consequences such
as stigma and discrimination which have negative impacts
on QoL [4-6]. QoL is also affected by several clinical andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Socio-demographic and clinical characteristics of TB/HIV co-infected and HIV-infected patients without TB
Variables TB/HIV co-infected patients (n = 97) HIV-infected patients without TB (n = 455) P-Value
Age in years, Mean (SD) 34.5 (9.5) 33.4 (8.1) 0.2
Sex
Male 43 (44.3%) 185 (40.6%) 0.5
Female 54 (55.7%) 270 (59.4%)
Employment
Unemployed 7 (7.2%) 52 (11.4%) 0.2
Employed 90 (92.8%) 403 (88.6%)
Have income source
Yes 69 (71.1%) 316 (69.5%) 0.7
No 28 (28.9%) 139 (30.5%)
Have social support
Yes 11(11.3%) 63 (13.8%) 0.5
No 86 (87.7%) 392 (86.2%)
WHO staging
Stage I - 71(15.6%) 0.000
Stage II - 64 (14.1%)
Stage III 79 (81.4) 216 (47.5%)
Stage IV 18 (18.6%) 65 (14.2%)
Mean CD4 lymphocyte count, (median) 392.6 (375.0) (n = 24) 383.7 (358.0) (n = 160) 0.8
Missed at least one dose of anti-TB treatment 7 (7.2%) - -
Missed at least one dose of ART 3(3.1) 7 (1.5%) 0.535
Lost to follow-up 27(21%) 10 (2.2%) 0.000
Table 2 Change in QoL among TB/HIV co-infected
patients after 6 months of treatment









Physical 13.3 (4.4) 17.9 (2.5) 5.1 (4.2 – 6.0) 0.000
Psychological 15.0 (3.2) 17.9 (1.8) 3.3 (2.6 – 4.0) 0.000
Level of independence 11.7 (3.7) 17.0 (2.4) 5.7 (4.9 – 6.6) 0.000
Social relationships 12.2 (3.7) 14.5 (2.5) 2.6 (1.7 – 3.5) 0.000
Environmental health 11.6 (3.1) 14.2 (2.7) 2.8 (2.1 – 3.6) 0.000
Spirituality health 16.5 (4.0) 19.0 (1.7) 3.1 (2.3 – 4.0) 0.000
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conducted in 2003 and 2004 among 947 HIV-infected
adults initiating highly active antiretroviral therapy in
Uganda, the overall score of QoL significantly increased
from the baseline and most of the gains were achieved by
the third month of therapy. While several clinical, psycho-
social and socio-demographic factors predicted QOL at
ART initiation, financial dependence on others was the
only remaining predictor after controlling for time on
ART [7]. Another cohort study among men in USA
showed that higher family support and CD4 lymphocyte
counts at baseline were predictive of improved changes in
physical and social functioning over time, and higher
depressive symptoms at baseline were predictor of dimin-
ished role functioning, emotional well-being, and general
health perception [8]. Whereas a prospective cohort study
conducted among 1053 patients in France revealed that
baseline CD4 lymphocyte count, time since HIV diagnosis,
undetectable viral load, and lower number of self-reported
symptoms were predictors of QoL [9].
Other predictors of QoL include poor social support
[10], depression [6,10,11], unemployment [12] or financial
dependence on others [6,7], older age [13] and being
female [14].Many studies have documented significant improvements
in QoL during ART [7,13,15]. There is however a dearth
of literature on the impact of tuberculosis (TB)/HIV
co-infection on QoL. From February to April 2009, we
conducted a QoL survey among HIV infected patients
with and without TB in three hospitals in Ethiopia [6].
This study showed that TB/HIV co-infected patients
had poorer QoL life than HIV infected patients without
TB. In this paper, we describe the change in QoL of the
same patients after 6-months of treatment.
Table 3 Change in QoL among HIV infected patients
without TB after 6 months of treatment









Physical 16.8 (2.8) 17.5 (2.5) 0.7 (0.4 – 1.1) 0.000
Psychological 16.2 (2.5) 17.4 (2.2) 1.2 (0.9 – 1.5) 0.000
Level of independence 15.0 (2.8) 16.6 (2.6) 1.6 (1.3 – 2.0) 0.000
Social relationships 13.6 (2.9) 14.3 (2.8) 0.6 (0.2 – 1.0) 0.002
Environmental health 12.4 (2.7) 13.7 (2.7) 1.2 (0.9 – 1.6) 0.000
Spiritual health 17.9 (2.9) 18.5 (2.3) 0.7 (0.4 – 1.0) 0.000
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Study settings and population
From February to April 2009, 465 HIV-infected patients
without TB and 124 TB/HIV co-infected patients who were
taking ART in three hospitals in Ethiopia were enrolled in a
prospective study. The patient selection process was
described in our previous paper [6]. In brief, at Jimma,
Nekemte and Adama hospitals, for each TB/HIV co-infected
patient, 3 HIV-infected patients without TB were selected
using a simple random sampling technique. All TB/HIV
co-infected patients were in the intensive phase of anti-TB
treatment. Exclusion criteria for both groups included age
less than 15 years, the presence of an opportunistic infec-
tion or a known chronic illness like diabetes mellitus and
hypertension. Patients were followed up monthly.
Data collection procedures and follow up
Diagnoses of TB and HIV were based on national guide-
lines [16]. Smear microscopy was the major diagnostic tool
for pulmonary TB. TB lymphadenitis was diagnosed based
on clinical parameters and cytological examination of an
aspirate obtained by fine needle aspiration. Patients with
HIV infection were considered not to have TB if they did
not present with any of the TB clinical symptoms [16].
During each clinic visit, patients were thoroughly assessed
by trained nurses for drug side effects, general health status
and presence of symptoms of opportunistic infection
including TB. CD4 lymphocyte count and WHO clinical
staging were extracted from the patients’ record at baseline
and at the 6th months of follow up. QoL was measured atTable 4 Comparison of QoL among TB/HIV co-infected and H




Physical 5.1 (4.2 – 6.0) 0
Psychological 3.3 (2.6 – 4.0) 1
Level of independence 5.7 (4.9 – 6.6) 1
Social relationships 2.6 (1.7 – 3.5) 0
Environmental health 2.8 (2.1 – 3.6) 1
Spiritual health 3.1 (2.3 – 4.0) 0baseline and after 6 months of follow up through face
to face interviews using the short Amharic version of
the World Health Organization QoL Instrument for HIV
infected patients (WHOQOL HIV-Brief) [17]. This QoL in-
strument has been described in our previous article [6]. In
brief, it consisted of 31 Likert scale questions in 6 domains
of QoL: Physical health (4 items); psychological wellbeing
(5 items); social relationship (4 items); environmental health
(8 items); level of independence (4 items) and spiritual
health (4 items). There were two questions about general
QoL and perceived general health.
Common Mental Disorder (CMD) was measured
using the Kessler 10 scales [18]. This instrument has 10
questions each asking the respondent how often they
experienced symptoms during the previous 30 days and
containing 5-point Likert scales (1 = never, 2 = a small part
of the time, 3 = some of the time, 4 = most of the times,
5 = all of the time). The Kessler-10 scale was validated
in Ethiopia and used extensively [19,20].
Data analysis
Data were analyzed using the SPSS version 16.0 and
STATAW version 11 software. Domain scores in the
WHOQOL-HIV-Brief were scaled in positive direction
with higher score denoting good quality of life. Negative
questions like pain and discomfort were recorded so that
higher scores reflected better QoL. Mean scores of items
within each domain were used to calculate the domain
score. Mean scores were then multiplied by 4 in order to
make domain scores comparable with the scores used in
the World Health Organization QoL (WHOQOL-100). We
used t-test and F-test to compare means between groups.
QoL was treated as continuous variable. CMD was
categorized as normal (score <20), moderate (score 20–24),
severe (score 25–29) and very severe (score above 30) as
proposed previously [18,21]. Paired T-test was used to
compare repeated measurements of QoL at baseline
and at 6 month. Multivariate analysis was conducted
using generalized estimating equations (GEE) using the
Gaussian family and the identity link function. In this
model, the correlations between the baseline and 6-month
measurements were taken into account. Variables with






.7 (0.4 – 1.1) 4.4 (3.4 - 5.4) 0.000
.2 (0.9 – 1.5) 2.1 (1.4 - 2.9) 0.000
.6 (1.3 – 2.0) 4.1 (3.2 - 5.0) 0.000
.6 (0.2 – 1.0) 1.2 (1.1 - 2.9) 0.000
.2 (0.9 – 1.6) 1.6 (0.8 - 2.4) 0.000
.7 (0.4 – 1.0) 2.4 (1.5 - 3.3) 0.000
Table 5 Predictors of physical QoL among TB/HIV
co-infected and HIV-infected patients without TB
TB/HIV co-infected HIV-infected without TB
Variables β (SE) P-value β (SE) P-value
Sex
Male 1.00 1.00
Female −0.26 (0.4) 0.5 0.07 0.7
Mean CD4 count
<50 1.00 1.00
50-100 0.98 (0.8) 0.2 0.13 (0.3) 0.7
101-200 0.28 (0.8) 0.7 0.17 (0.28) 0.5
>200 0.20 (0.8) 0.8 0.19 (0.29) 0.5
WHO staging
I NA 1.00
II NA −0.11 (0.3) 0.7
III 1.00 −0.28 (0.3) 0.3
VI −0.91 (0.6) 0.1 0.05 (0.3) 0.9
Adherence to ART
Yes 1.00 1.00
No −0.61 (1.2) 0.6 −0.31 (0.5) 0.5
Adherence to anti-TB
Yes 1.00 NA
No 0.27 (1.4) 0.8
Social support
Yes 1.00 1.00
No −0.27 (0.5) 0.6 0.11 (0.3) 0.7
Source of income
Yes 1.00 1.00
No −0.49 (0.6) 0.4 −0.35 (0.2) 0.07
CMD
Normal 1.00 1.00
Moderate −0.21 (0.7) 0.8 −0.69 (0.2) 0.001
High −0.88 (0.6) 0.2 −1.37 (0.2) 0.000
Very high −2.48 (0.6) 0.000 −2.34 (0.3) 0.000
Employment
Yes 1.00 1.00
No 0.42 (0.7) 0.6 −0.17 (0.3) 0.6
*NA = not applicable.
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or equal to 0.05 was taken as the cut-off value for
statistical significance.
Ethical clearance
Ethical clearance was obtained from the Jimma University
ethical review board. Written informed consent was
obtained from the study participants. To ensure confiden-
tiality, the data were anonymised before they were analyzed.
Results
After 6 months, 455 (98%) of the 465 HIV-infected
patients and 97 (78%) of the 124 TB/HIV co infected
patients were still in follow up. Thirty seven (6.3%) were
lost to follow-up. There were no significant difference in
baseline CD4 lymphocyte count between patients who
completed the study and those lost to follow up, none-
theless most of the lost to follow-up were in WHO stage
3 and 4(P = 0.002).
Over the 6 months period, 5/455(1.1%) patients with
HIV infection developed pulmonary TB, 7 (7.2%) of TB/
HIV co-infected patients and 10 (1.8%) of all patients
missed their anti-TB treatment and ART at least once.
Twenty five percent of TB/HIV co-infected patients had
their CD4 lymphocyte measured both at baseline and
after 6 months, compared to 35% of HIV infected patients
without TB (Table 1).
Change in quality of life
In all patients, after 6 months of treatment there was a
significant improvement of QoL in all its dimensions
(physical, psychological, social relationships, environmental,
spiritual and level of dependence) (Table 2 and 3).
The change in QoL in all its dimension was more
pronounced for TB/HIV co-infected patients compared
to HIV infected patients without TB. For instance, there
was a 4.4 unit difference between TB/HIV co-infected
and HIV infected patients without TB in the physical
dimension of QoL (Table 4).
Predictors of change in QoL
Although not statistically significant, lack of social support,
absence of a source of income and poor adherence to ART
had a negative effect on the physical dimension of QoL of
all patients. A severe form of CMD was strongly associated
with poorer physical QoL among TB/HIV co-infected indi-
viduals (β = −2.84; P = 0.000) and HIV infected patients
without TB (β = −2.34; P = 0.000) (Table 5).
Though not statistically significant, lack of social support
had a negative effect on psychological QoL of TB/HIV
co-infected patients (β = −0.28, P = 0.4) and HIV infected
patients without TB (β = −0.44, P = 0.2). A severe form of
CMD was strongly associated with poorer psychological
QoL in both groups of patient (Table 6).Discussion
This study shows that all the dimensions of QoL have
significantly improved after 6 months of treatment in
both patient groups. However, the improvement in QoL
was more pronounced for TB/HIV co-infected patients.
The significant improvement of the physical quality of
life of TB/HIV co-infected patients could be explained
by the relief of TB symptoms during anti-TB treatment
[22]. Some studies have documented that the major gain
Table 6 Predictors of psychological QoL among TB/HIV
co-infected and HIV-infected patients without TB
TB/HIV co-infected HIV-infected patients
without TB
Variables β (SE) P-value β (SE) P-value
Sex
Male 1.00 1.00
Female −0.69 (0.3) 0.03 −0.22 (0.2) 0.1
Mean CD4 count
<50 1.00 1.00
50-100 1.15 (0.6) 0.06 −0.16 (0.3) 0.6
101-200 0.70 (0.6) 0.2 −0.12 (0.2) 0.6
>200 0.53 (0.6) 0.3 −0.01 (0.2) 0.969
WHO staging
I 1.00
II −0.36 (0.3) 0.2
III 1.00 −0.10 (0.3) 0.7
VI −0.42 (0.4) 0.3 −0.04 (0.3) 0.9
Adherence to ART
Yes 1.00 1.00
No 0.06 (0.8) 0.9 0.40 (0.5) 0.4
Adherence to anti-TB
Yes 1.00 NA
No 0.43 (1.0) 0.7
Social support
Yes 1.00 1.00
No −0.28 (0.4) 0.5 −0.44 (0.2) 0.06
Source of income
Yes 1.00 1.00
No −0.06 (0.4) 0.9 −0.56 (0.2) 0.001
CMD
Normal 1.00 1.00
Moderate −0.87 (0.5) 0.08 −0.51 (0.2) 0.010
High −0.76 (0.4) 0.09 −1.71 (0.2) 0.000
Very high −2.29 (0.4) 0.000 −2.04 (0.3) 0.000
Employment
yes 1.00 1.00
No 0.04 (0.5) 0.9 −0.40 0.1
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first three months of initiating of ART [8,23].
In our study, income and employment did not influence
significantly QoL but this may be because of the small
sample size of the study and most study participants had a
similar socio-economic background. Indeed, other studies
have shown that socio-economic status and social support
are very important predictors of QoL of persons with HIV
infection [12,16]. Gender also did not predict QoL in ourstudy in contrast with some other studies that reported
lower QoL among women [14,24,25]. This could be due
to the presence of some income generating schemes by
Civil Society Organizations targeting only HIV infected
women in Ethiopia.
In contrast with other studies, we were unable to
demonstrate that a lower CD4 lymphocyte count did
not predicted a worse QoL [17]. This could be because
of the small sample size of the study and secondly,
all patients received adequate treatment with good
adherence rate.
In our study, the presence of CMD was a main predictor
of QoL after controlling other confounding variables. This
suggests that screening and treatment of CMDs could be
an important strategy towards improving the QoL of
patients with TB and/or HIV in Ethiopia.
Our study has several limitations. First, the lost to follow
up due to unknown reasons and missing data on CD4
count, particularly among TB/HIV co-infected patients,
may have obscured the effect of CD4 lymphocyte count
and WHO clinical staging on quality of life. Second, the
cause-effect relationship between CMD and QoL could
not be established. Third, we did not gather comprehensive
information regarding income and occupation which might
have impact on QoL.
Conclusion
Our study shows that ART and anti-TB treatment improves
all dimensions of QoL. CMD is a major predictor of poor
QoL. We recommend that the ministry of health in collab-
oration with partners shall integrate mental health services
into the TB/HIV programs and train health care providers
to timely identify and treat CMD to improve QoL.
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